The present invention relates to a heterocyclic compound, a pharmaceutical composition containing same, and a preparation method therefor, as well as an application of the heterocyclic compound as mitogen-activated protein kinase interacting kinases 1 and 2-MNK1/MNK2 inhibitors. The inhibitor is a heterocyclic compound as shown in a formula (I), or pharmaceutically acceptable salts, prodrugs, solvent compounds, polymorphs, isomers, and stable isotope derivatives thereof, or pharmaceutical compositions containing same. The compounds provided by the present invention can be used for treating or preventing MNK-mediated related diseases, such as cancers.